Skip to main content
SpringerLink
Log in

Interstitielle Lungenerkrankung

Lungenmanifestationen rheumatischer Erkrankungen schon früh mitbedenken

  • CME Fortbildung
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Leuschner G, Neurohr C. What rheumatologists can learn from pneumologists. Z Rheumatol. 2018;77:477-83

  2. Fischer A, Strek ME, Cottin V et al. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol. 2019;71:182-95

  3. Hyldgaard C, Hilberg O, Pedersen AB et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: Comorbidity and mortality. Ann Rheum Dis. 2017;76:1700-6

  4. Juge PA, Lee JS, Ebstein E et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med. 2018;379:2209-19

  5. Krause A, Rubbert-Roth A. Pulmonary involvement in rheumatoid arthritis. Z Rheumatol. 2019;78:228-35

  6. Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48

  7. Adler S, Huscher D, Siegert E et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group. Arthritis Res Ther. 2018;20:17

  8. Goh NS, Hoyles RK, Denton CP et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol. 2017;69:1670-8

  9. Hoffmann-Vold AM, Maher TM, Philpot EE et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;2:e71-83

  10. Flament T, Bigot A, Chaigne B et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev. 2016;25:110-23

  11. Barba T, Mainbourg S, Nasser M et al. Lung Diseases in Inflammatory Myopathies. Semin Respir Crit Care Med. 2019;40:255-70

  12. Bauhammer J, Fiehn C. Antisynthetase syndromes. Z Rheumatol. 2019;78:645-55

  13. Nasser M, Cottin V. The Respiratory System in Autoimmune Vascular Diseases. Respiration. 2018;96:12-28

  14. Fischer A, Antoniou KM, Brown KK et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976-87

  15. Jee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs. 2019;79:1511-28

  16. Duarte AC, Cordeiro A, Fernandes BM et al. Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol. 2019;38:2001-9

  17. Fernández-Díaz C, Loricera J, Castañeda S et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48:22-7

  18. Flaherty KR, Wells AU, Cottin V et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718-27

  19. Distler O, Highland KB, Gahlemann M et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-28

  20. Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI et al. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017;36:1493-500

  21. Kiely P, Busby AD, Nikiphorou E et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9:e028466. https://doi.org/10.1136/bmjopen-2018-028466

  22. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C et al. Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases. Semin Arthritis Rheum. 2011;41:256-64

  23. Prasse A, Bonella F, Müller-Ladner U et al. Treatment of systemic sclerosis-associated interstitial lung disease. Z Rheumatol. 2019; https://doi.org/10.1007/s00393-019-00724-y

  24. Tashkin DP, Roth MD, Clements PJ et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-19

  25. Khanna D, Denton CP, Lin CJF et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77:212-20

  26. Barba T, Fort R, Cottin V et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2019;18:113-22

  27. Hornig J, Weinhage T, Schmidt LH et al. Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol. 2018;77:952-7

  28. Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis - Associated Interstitial Lung Disease. N Engl J Med. 2019;381:291-3

  29. Thompson GE, Specks U. Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. Clin Chest Med. 2019;40:573-82

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin, Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, 14109 Berlin-Wannsee, Deutschland

    Andreas Krause &  Michael Kreuter

Authors
  1. Andreas Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kreuter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Krause.

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen und im Zusammenhang mit diesem Beitrag keine Interessenkonflikte bestehen.

Als mögliche Interessenkonflikte könnten angesehen werden: Prof. Dr. Andreas Krause erhielt Vortrags- und Beratungshonorare von Boehringer Ingelheim und Roche. Prof. Dr. Michael Kreuter, erhielt Aufwandsentschädigungen für Beratungen von Boehringer Ingelheim und Roche und seine Institution für wissenschaftliche Grants von Boehringer Ingelheim und Roche.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krause, A., Kreuter, M. Lungenmanifestationen rheumatischer Erkrankungen schon früh mitbedenken. Pneumo News 12, 33–42 (2020). https://doi.org/10.1007/s15033-020-1895-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-020-1895-1

Search

Navigation